-
Je něco špatně v tomto záznamu ?
Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis
H. Vaverková, D. Karásek, D. Novotný, D. Jackuliaková, J. Lukeš, M. Halenka, J. Frohlich
Jazyk angličtina Země Spojené státy americké
Typ dokumentu práce podpořená grantem
Grantová podpora
NR9068
MZ0
CEP - Centrální evidence projektů
- MeSH
- apolipoproteiny B krev MeSH
- biomarkery farmakologické krev MeSH
- dospělí MeSH
- inzulinová rezistence MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- metabolický syndrom krev MeSH
- nemoci koronárních tepen krev MeSH
- rizikové faktory MeSH
- statistika jako téma MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
OBJECTIVE: To characterize the differences in various risk factors for atherosclerosis between individuals with apoB higher (H) and lower (L) than predicted from regression equation apoB vs LDL-C. METHODS: We evaluated 391 dyslipidemic subjects not treated with hypolipidemic drugs. The measured parameters included lipid profile, apolipoproteins A-1 and B, markers of insulin resistance and inflammation/hemostasis. RESULTS: Correlation coefficient between apoB and LDL-C was 0.9 (p<0.0001). Individuals with H apoB compared to L apoB had significantly higher sex and age adjusted BMI, waist circumference, insulin, HOMA (fasting insulinglucose/22.5), C-peptide, proinsulin, PAI-1, sICAM-1, sVCAM-1, t-PA, vWF, frequency of metabolic syndrome and lower values of TC, LDL-C and HDL-C (p<0.05 to <0.001 for all parameters). CONCLUSION: Individuals with apoB higher than predicted by their LDL-C levels are more insulin resistant and have more atherogenic risk profile. Thus, at least for dyslipidemic patients with high cardiometabolic risk, apoB is a more appropriate marker of risk than LDL-C.
Citace poskytuje Crossref.org
- 000
- 02630naa 2200433 a 4500
- 001
- bmc11022398
- 003
- CZ-PrNML
- 005
- 20140228143544.0
- 008
- 110729s2009 xxu e Eng||
- 009
- AR
- 024 __
- $a 10.1016/j.clinbiochem.2009.05.004 $2 doi
- 035 __
- $a (PubMed)19450572
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vaverková, Helena, $d 1942- $7 nlk20000083882
- 245 10
- $a Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis / $c H. Vaverková, D. Karásek, D. Novotný, D. Jackuliaková, J. Lukeš, M. Halenka, J. Frohlich
- 314 __
- $a 3rd Department of Internal Medicine, University Hospital Olomouc, Czech Republic. helena.vaverkova@fnol.cz
- 520 9_
- $a OBJECTIVE: To characterize the differences in various risk factors for atherosclerosis between individuals with apoB higher (H) and lower (L) than predicted from regression equation apoB vs LDL-C. METHODS: We evaluated 391 dyslipidemic subjects not treated with hypolipidemic drugs. The measured parameters included lipid profile, apolipoproteins A-1 and B, markers of insulin resistance and inflammation/hemostasis. RESULTS: Correlation coefficient between apoB and LDL-C was 0.9 (p<0.0001). Individuals with H apoB compared to L apoB had significantly higher sex and age adjusted BMI, waist circumference, insulin, HOMA (fasting insulinglucose/22.5), C-peptide, proinsulin, PAI-1, sICAM-1, sVCAM-1, t-PA, vWF, frequency of metabolic syndrome and lower values of TC, LDL-C and HDL-C (p<0.05 to <0.001 for all parameters). CONCLUSION: Individuals with apoB higher than predicted by their LDL-C levels are more insulin resistant and have more atherogenic risk profile. Thus, at least for dyslipidemic patients with high cardiometabolic risk, apoB is a more appropriate marker of risk than LDL-C.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a apolipoproteiny B $x krev $7 D001055
- 650 _2
- $a nemoci koronárních tepen $x krev $7 D003324
- 650 _2
- $a biomarkery farmakologické $x krev $7 D054316
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inzulinová rezistence $7 D007333
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolický syndrom $x krev $7 D024821
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a statistika jako téma $7 D013223
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Karásek, David $7 stk2007415300
- 700 1_
- $a Novotný, Dalibor, $d 1965-2015 $7 xx0041926
- 700 1_
- $a Jackuliaková, Dagmar $7 xx0101837
- 700 1_
- $a Lukeš, Jiří $7 xx0070976
- 700 1_
- $a Halenka, Milan $7 xx0047393
- 700 1_
- $a Frohlich, Jiří, $d 1942- $7 xx0064831
- 773 0_
- $t Clinical Biochemistry $w MED00001119 $g Roč. 42, č. 12 (2009), s. 1246-1251
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110801153712 $b ABA008
- 991 __
- $a 20140228143545 $b ABA008
- 999 __
- $a ok $b bmc $g 881776 $s 732318
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00001119 $b 42 $c 12 $d 1246-1251 $m Clinical biochemistry $n Clin Biochem
- GRA __
- $a NR9068 $p MZ0
- LZP __
- $a 2011-4B09/jvme